These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 24135246)

  • 1. Protein kinase Cs in lung cancer: a promising target for therapies.
    Fan C; Li Y; Jia J
    J Cancer Res Ther; 2013 Sep; 9 Suppl 2():S74-9. PubMed ID: 24135246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel small-molecule inhibitor of protein kinase Ciota blocks transformed growth of non-small-cell lung cancer cells.
    Stallings-Mann M; Jamieson L; Regala RP; Weems C; Murray NR; Fields AP
    Cancer Res; 2006 Feb; 66(3):1767-74. PubMed ID: 16452237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting phosphoinositide 3-kinase signalling in lung cancer.
    Wojtalla A; Arcaro A
    Crit Rev Oncol Hematol; 2011 Nov; 80(2):278-90. PubMed ID: 21316260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the oncogenic protein kinase Ciota signalling pathway for the treatment of cancer.
    Fields AP; Frederick LA; Regala RP
    Biochem Soc Trans; 2007 Nov; 35(Pt 5):996-1000. PubMed ID: 17956262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical and clinical development of novel agents that target the protein kinase C family.
    Serova M; Ghoul A; Benhadji KA; Cvitkovic E; Faivre S; Calvo F; Lokiec F; Raymond E
    Semin Oncol; 2006 Aug; 33(4):466-78. PubMed ID: 16890801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Agents in the preclinical development stage for non-small cell lung cancer.
    Sacco PC; Sgambato A; Casaluce F; Maione P; Rossi A; Palazzolo G; Napolitano A; Gridelli C
    Expert Rev Anticancer Ther; 2015; 15(11):1361-6. PubMed ID: 26485341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine.
    Pilotto S; Peretti U; Novello S; Rossi G; Milella M; Giaj Levra M; Ciuffreda L; Massari F; Brunelli M; Tortora G; Bria E
    Expert Opin Pharmacother; 2013 Apr; 14(5):597-608. PubMed ID: 23472711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line treatment for advanced nonsmall cell lung cancer harboring activating epidermal growth factor receptor mutation: epidermal growth factor receptor tyrosine kinase inhibitors or chemotherapy?
    Gridelli C
    Curr Opin Oncol; 2011 Mar; 23(2):131-2. PubMed ID: 21307676
    [No Abstract]   [Full Text] [Related]  

  • 10. Multitargeted inhibitors in lung cancer: new clinical data.
    Bar J; Herbst RS; Onn A
    Clin Lung Cancer; 2008; 9 Suppl 3():S92-9. PubMed ID: 19419930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzastaurin, a protein kinase Cbeta- selective inhibitor, and its potential application as an anticancer agent in lung cancer.
    Herbst RS; Oh Y; Wagle A; Lahn M
    Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4641-6. PubMed ID: 17671157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitors of the anaplastic lymphoma kinase.
    Mologni L
    Expert Opin Investig Drugs; 2012 Jul; 21(7):985-94. PubMed ID: 22612599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor receptor: pathway, therapies, and pipeline.
    Goffin JR; Zbuk K
    Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New targets for non-small-cell lung cancer therapy.
    Alvarez M; Roman E; Santos ES; Raez LE
    Expert Rev Anticancer Ther; 2007 Oct; 7(10):1423-37. PubMed ID: 17944567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go.
    Patel JD; Pasche B; Argiris A
    Crit Rev Oncol Hematol; 2004 Jun; 50(3):175-86. PubMed ID: 15182824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted therapy of non-small-cell lung carcinoma.
    Tiwari D; Brodie SA; Brandes JC
    Ther Adv Respir Dis; 2012 Feb; 6(1):41-56. PubMed ID: 21730004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting EGFR in non-small-cell lung cancer: lessons, experiences, strategies.
    Stella GM; Luisetti M; Inghilleri S; Cemmi F; Scabini R; Zorzetto M; Pozzi E
    Respir Med; 2012 Feb; 106(2):173-83. PubMed ID: 22104541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting protein kinase C subtypes in pancreatic cancer.
    Storz P
    Expert Rev Anticancer Ther; 2015 Apr; 15(4):433-8. PubMed ID: 25604078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered protein kinase C (PKC) isoforms in non-small cell lung cancer cells: PKCdelta promotes cellular survival and chemotherapeutic resistance.
    Clark AS; West KA; Blumberg PM; Dennis PA
    Cancer Res; 2003 Feb; 63(4):780-6. PubMed ID: 12591726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR.
    Bell DW; Gore I; Okimoto RA; Godin-Heymann N; Sordella R; Mulloy R; Sharma SV; Brannigan BW; Mohapatra G; Settleman J; Haber DA
    Nat Genet; 2005 Dec; 37(12):1315-6. PubMed ID: 16258541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.